臨床整形外科54巻7号

2019年07月発行

誌上シンポジウム 骨軟部腫瘍の薬物治療アップデート

骨肉腫に対する最新の薬物療法

著者： 平賀博明¹

所属機関： ¹国立病院機構北海道がんセンター骨軟部腫瘍科

ページ範囲：P.659 - P.664

　骨肉腫患者の初期治療は補助化学療法と手術が標準療法であるが，直近30年間で新規薬剤の優越性を示した第Ⅲ相試験はなく，治療開発は低迷している．再発進行例については小分子キナーゼ阻害薬と免疫チェックポイント阻害薬を中心に治療開発が行われており，特に前者では効果が期待される薬剤が報告されている．しかし，治療開発は主に医師主導試験が中心であり，その開発スピードは遅いため，医師と企業の協力が必要である．

参考文献

1) Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;314(25):1600-6.

2) Eilber F, Giuliano A, Eckardt J, et al. Adjuvant chemotherapy for osteosarcoma:a randomized prospective trial. J Clin Oncol 1987;5(1):21-6.

3) Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma:a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005;23(9):2004-11.

4) Bielack SS, Smeland S, Whelan JS, et al. Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP:first results of the EURAMOS-1 good response randomized controlled trial. J Clin Oncol 2015;33(20):2279-87.

5) Marina NM, Smeland S, Bielack SS, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1):an open-label, international, randomised controlled trial. Lancet Oncol 2016;17(10):1396-408.

6) Piperno-Neumann S, Le Deley MC, Rédini F, et al. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006):a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2016;17(8):1070-80.

7) Jimmy R, Stern C, Lisy K, et al. Effectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma:a systematic review. JBI Database System Rev Implement Rep 2017;15(8):2113-52.

8) Thanindratarn P, Dean DC, Nelson SD, et al. Advances in immune checkpoint inhibitors for bone sarcoma therapy. J Bone Oncol 2019;15:100221. doi:10.1016/j.jbo.2019.100221.

9) Zhu Z, Jin Z, Zhang M, et al. Prognostic value of programmed death-ligand 1 in sarcoma:a meta-analysis. Oncotarget 2017;8(35):59570-80.

10) Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028):a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 2017;18(11):1493-501.

11) Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy:an Italian Sarcoma Group study. Ann Oncol 2012;23(2):508-16.

12) Grignani G, Palmerini E, Ferraresi V, et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment:a non-randomised phase 2 clinical trial. Lancet Oncol 2015;16(1):98-107.